No abstract available
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Viral / biosynthesis
-
Antibodies, Viral / blood
-
Antibodies, Viral / immunology*
-
Antigens, Viral / immunology*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / immunology*
-
COVID-19 / prevention & control*
-
COVID-19 Vaccines / immunology*
-
Cancer Care Facilities
-
Cohort Studies
-
Female
-
Health Personnel
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Humans
-
Immunoglobulin G / biosynthesis
-
Immunoglobulin G / blood
-
Immunoglobulin G / immunology
-
Immunoglobulin M / biosynthesis
-
Immunoglobulin M / blood
-
Immunoglobulin M / immunology
-
Immunotherapy, Adoptive / adverse effects
-
Institutionalization
-
Lymphoma, B-Cell / immunology*
-
Lymphoma, B-Cell / therapy
-
Lymphoma, T-Cell / immunology
-
Lymphoma, T-Cell / therapy
-
Male
-
Middle Aged
-
Multiple Myeloma / immunology
-
Multiple Myeloma / therapy
-
Nursing Homes
-
Patients
-
Prospective Studies
-
SARS-CoV-2 / immunology*
-
Spike Glycoprotein, Coronavirus / immunology*
-
Vaccination*
Substances
-
Antibodies, Viral
-
Antigens, Viral
-
Antineoplastic Agents
-
COVID-19 Vaccines
-
Immunoglobulin G
-
Immunoglobulin M
-
Spike Glycoprotein, Coronavirus
-
spike protein, SARS-CoV-2